Sign in
CompletedNo phase

SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation

Key facts

Who runs it
Edwards Lifesciences
Where
Atlanta, Detroit, Evanston, Los Angeles, Murray, Norfolk, Rochester, and San Francisco, United StatesSee the 8 sitesAlso in 1 other country, 1 site
Trial code
Status
Completed
People taking part
72 people enrolled
Started
14 Sept 2017
Ended
20 Aug 2026
Type of study
Interventional
Treatments tested
  • Edwards SAPIEN M3 System
Record updated
25 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • 18 years of age or older
  • MR ≥ 3+
  • NYHA functional class ≥ II
  • High risk of cardiovascular surgery
  • Hemodynamically stable while on heart failure medication for at least 2 weeks before the procedure
  • The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent

Who cannot take part

  • Prior surgical or interventional treatment of mitral valve preventing appropriate device access and deployment
  • Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
  • Inability to tolerate or a medical condition precluding treatment with anti-thrombotic therapy
  • Patients with renal insufficiency or receiving renal replacement therapy
  • Participating in another investigational drug or device study
  • Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
  • History of cardiac transplantation
  • History of recurrent and/or unprovoked deep vein thrombosis or pulmonary embolism
  • Clinically significant untreated coronary artery disease requiring revascularization
  • Stroke or transient ischemic attack within 90 days of the procedure
  • Myocardial infarction within 30 days of the procedure
  • Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy, or hypercoagulable states
  • Irreversible, severe pulmonary hypertension
  • Liver disease or significantly abnormal liver function test results
  • LV Ejection Fraction <30%
  • Mitral anatomy that would preclude appropriate delivery and deployment of the dock or valve
  • Significant risk of LVOT obstruction
  • Severe right ventricular dysfunction
  • Patient is inoperable
  • Need for aortic, tricuspid or pulmonic valve replacement
  • Presence of mechanical aortic valve prosthesis
  • Active bacterial endocarditis within 180 days of the procedure
  • Hospitalization for CHF or hemodynamic instability requiring inotropic support or intra-aortic balloon pump within 30 days
  • Refusal of blood products
  • Female who is pregnant or lactating
  • Estimated life expectancy < 12 months

Where in United States

Also in 1 other country, 1 site

  • Emory UniversityAtlanta, United States
  • Henry Ford HospitalDetroit, United States
  • Evanston/ Northshore UniversityEvanston, United States
  • Cedars-Sinai Medical Center Heart InstituteLos Angeles, United States
  • Intermountain Medical CenterMurray, United States
  • Sentara Cardiovascular Research InstitutionNorfolk, United States
  • Mayo ClinicRochester, United States
  • California Pacific Medical CenterSan Francisco, United States

About the trial

What the trial wants to find out

This study will evaluate the safety and functionality of the SAPIEN M3 System in patients with symptomatic, severe MR and will provide guidance for future clinical study designs utilizing the SAPIEN M3 System.

The group in the trial

  • TMVRTreatment being tested

    Subjects will undergo transcatheter mitral valve replacement

    Treatment: Edwards SAPIEN M3 System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
Record updated
25 September 2026